迈克生物
(300463)
| 流通市值：71.56亿 | | | 总市值：89.18亿 |
| 流通股本：4.92亿 | | | 总股本：6.12亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,947,615,476.64 | 1,278,911,868.07 | 616,367,154.02 | 2,895,769,512.02 |
| 营业收入 | 1,947,615,476.64 | 1,278,911,868.07 | 616,367,154.02 | 2,895,769,512.02 |
| 二、营业总成本 | 1,641,999,626.83 | 1,078,405,645.65 | 483,286,866.6 | 2,506,578,260.55 |
| 营业成本 | 833,709,893.93 | 549,931,797.52 | 262,495,245.94 | 1,295,317,800.53 |
| 税金及附加 | 15,902,077.28 | 11,849,877.07 | 4,033,322.9 | 27,142,111.91 |
| 销售费用 | 437,353,017.09 | 287,659,610.26 | 120,714,364.34 | 652,407,225.96 |
| 管理费用 | 117,401,811.32 | 77,030,727.05 | 32,691,837.69 | 184,234,096.64 |
| 研发费用 | 223,099,816.06 | 144,497,068.23 | 59,524,079.57 | 324,166,528.78 |
| 财务费用 | 14,533,011.15 | 7,436,565.52 | 3,828,016.16 | 23,310,496.73 |
| 其中:利息费用 | 15,138,099.03 | 11,675,822.03 | 5,949,090.27 | 33,532,981.81 |
| 其中:利息收入 | 4,214,158.3 | 3,599,736.71 | 1,835,245.61 | 10,030,794.17 |
| 加:公允价值变动收益 | -8,668,000.15 | -2,221,009.33 | -1,583,386.21 | -7,076,745.18 |
| 加:投资收益 | 3,393,048.87 | 2,647,347.14 | 1,850,226.43 | 8,592,386.93 |
| 资产处置收益 | -5,797,227.7 | -3,429,889.27 | -1,384,763.4 | -4,165,350.13 |
| 资产减值损失(新) | -7,025,194.79 | -3,435,493.45 | -93,684.63 | -58,036,538.66 |
| 信用减值损失(新) | 9,064,673.29 | 14,045,578.66 | -4,863,951.07 | -36,373,435.06 |
| 其他收益 | 21,960,273.37 | 15,923,587.96 | 9,440,505.85 | 39,013,186.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 318,543,422.7 | 224,036,344.13 | 136,445,234.39 | 331,144,756.3 |
| 加:营业外收入 | 1,411,946.35 | 1,373,879.95 | 73,568.98 | 378,125.58 |
| 减:营业外支出 | 8,671,607.77 | 2,273,125.56 | 535,221.1 | 26,153,908.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 311,283,761.28 | 223,137,098.52 | 135,983,582.27 | 305,368,973.69 |
| 减:所得税费用 | 28,186,766.24 | 20,647,238.63 | 11,739,756.16 | 689,896.99 |
| 六、净利润 | 283,096,995.04 | 202,489,859.89 | 124,243,826.11 | 304,679,076.7 |
| 持续经营净利润 | 283,096,995.04 | 202,489,859.89 | 124,243,826.11 | 304,679,076.7 |
| 归属于母公司股东的净利润 | 281,372,336.41 | 201,725,714.09 | 120,442,248.9 | 312,618,556.85 |
| 少数股东损益 | 1,724,658.63 | 764,145.8 | 3,801,577.21 | -7,939,480.15 |
| (一)基本每股收益 | 0.46 | 0.33 | 0.2 | 0.51 |
| (二)稀释每股收益 | 0.46 | 0.33 | 0.2 | 0.51 |
| 八、其他综合收益 | -9,042,783.88 | -1,252,770.79 | -363,649.36 | -8,400,942.55 |
| 归属于母公司股东的其他综合收益 | -9,042,783.88 | -1,252,770.79 | -363,649.36 | -8,400,942.55 |
| 九、综合收益总额 | 274,054,211.16 | 201,237,089.1 | 123,880,176.75 | 296,278,134.15 |
| 归属于母公司股东的综合收益总额 | 272,329,552.53 | 200,472,943.3 | 120,078,599.54 | 304,217,614.3 |
| 归属于少数股东的综合收益总额 | 1,724,658.63 | 764,145.8 | 3,801,577.21 | -7,939,480.15 |
| 公告日期 | 2024-10-23 | 2024-08-02 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |